AmacaThera, a biotechnology startup co-founded by Molly Shoichet, has entered into a global licensing agreement valued at up to US$230 million with Pacira BioSciences. The partnership supports the development and commercialization of AMT-143, a long-acting, non-opioid anesthetic designed to improve post-operative pain management.
The agreement represents a significant step forward in advancing scalable, opioid-sparing solutions for surgical care. It also highlights the broad therapeutic potential of AmacaThera’s proprietary hydrogel drug delivery platform, which is being explored across multiple medical applications. Founded on research originating at the University of Toronto, AmacaThera continues to translate academic innovation into real-world impact.
Read the full press release here.